Why Gamida Cell Failed: Unit Economics | Startup Autopsy
€260M
Raised
26y
Time to collapse
€700M
Peak valuation
// startup autopsy
Gamida Cell
Gamida Cell spent 26 years developing a stem cell therapy for blood cancers, won FDA approval in 2023 — and filed for Chapter 11 bankruptcy in March 2024 because the approved drug could not generate enough revenue to survive.
Evaluating only Gamida Cell’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
Gamida Cell founded
DOWN ROUND
Down round or bridge financing
SHUTDOWN
Bankruptcy: Gamida Cell ceases operations
Full Analysis
Free · no account needed
Documented cause
Gamida Cell developed omidubicel (Omisirge), a nicotinamide-expanded stem cell product for bone marrow transplantation. The drug received FDA approval in April 2023 — a 25-year scientific milestone. However, the transplant center adoption was slower than projected, the patient population was narrow, and the commercial infrastructure costs exceeded revenues. The company filed for Chapter 11 in March 2024, less than a year after approval.
Lesson
“A narrow patient population and slow hospital adoption can sink even an approved drug — small markets require lean commercial structures, not full launch buildouts.”